FINNENCE ▪ THE WIRE FILE
THE WIRE · № 68997
News■ Unclear/unknown
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 12:00 UTC
LAST UPDATE2026-10-07 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Conference presentations of clinical data can shift sentiment but no efficacy or safety results are disclosed here.
Pipeline update without disclosed results
CATALYST TO WATCH
Actual data readout at the conference
MAIN RISK
Abstracts may disappoint on efficacy
FULL DISPATCH
– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium's Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity and Cognition, Novel Disability Measurement, and Nurr1-Mediated Neuronal Survival – – New Phase 2 CALLIPER...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds2026-10-07 12:02 UTC
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds2026-10-07 12:02 UTC
→CORRELATIONshares Healthcare
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
→CORRELATIONshares Healthcare
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
Why CVOTs Require a Different Approach: Optimizing Event Accrual to Reduce Trial Delays, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
Why CVOTs Require a Different Approach: Optimizing Event Accrual to Reduce Trial Delays, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC2026-10-07 12:30 UTC
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC2026-10-07 12:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.